A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Prexasertib (Primary) ; Cetuximab; Cisplatin; Fluorouracil; Folinic acid; Granulocyte colony-stimulating factors; LY 3023414; Pemetrexed
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 08 Mar 2017 Planned End Date changed from 1 Apr 2018 to 27 Apr 2019.
- 08 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 27 Apr 2019.
- 07 Jan 2016 Number of treatment arms changed from 3 to 5. Fluorouracil and LY3023414 drugs are added to the treatment. Primary end points are added accordingly as reported by ClinicalTrials.gov record.